Premium
Polymorphisms of 5‐hydroxytryptamine receptor type 3B gene and clinical characteristics for vomiting after breast surgery in chinese han female population
Author(s) -
Yan Ting,
Su Jiansheng,
Zhou Linying,
Zhang Liangcheng
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13386
Subject(s) - single nucleotide polymorphism , medicine , vomiting , breast cancer , univariate analysis , breast surgery , odds ratio , genotyping , population , genotype , anesthesia , multivariate analysis , surgery , cancer , biology , genetics , gene , environmental health
What is known and objective The 5‐hydroxytryptamine type 3B receptor ( HTR3B ) is involved in postoperative vomiting. We aimed to investigate whether genomic variations of rs1176744 and rs1672717 in HTR3B are associated with postoperative vomiting (POV) in the Chinese Han female population after surgery. Methods Five hundred and sixty‐eight female patients classified as ASA I‐II undergoing breast surgery under standard general anaesthesia were enrolled in the study. Episodes of POV in the first 24 h after surgery were recorded. Targeted single nucleotide polymorphisms (SNPs) in the HTR3B gene were identified by genotyping using the SNPscan TM technique. Univariate and multivariate analyses were conducted to investigate the association between SNPs and POV. Results We eventually analysed 407 subjects undergoing breast surgery under general anaesthesia. Of these, 104(25.6%) patients suffered POV within 24 h after surgery. In the multivariate logistic regression analysis, we found that age≥50 years ( p = 0.012) and longer duration of surgery ( p = 0.019) were independent risk factors for POV. Simultaneously, in the dominant model of rs1672717, compared with the AA genotype, GG+GA carriers suffered more POV (OR=1.669, p = 0.038). However, the use of atropine reduced the incidence of POV in our study ( p = 0.019). What is new and conclusion Our investigation demonstrated that polymorphism of rs1672717 ( HTR3B ) may be a genetic risk factor for developing POV. Trial registration: clinicaltrials.gov identifier: NCT03705026.